Related Announcements

PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

Issued by

National Institute of Neurological Disorders and Stroke (NINDS)

Purpose

The National Institute of Neurological Disorders and Stroke (NINDS) invites applications to expand existing NINDS awards that are not currently focused on pain research - to allow the research to develop such a focus. Active awards with project end dates in FY 2023 or later are eligible. The award may not be in a terminal no-cost extension or going into a no-cost extension in FY 2022.

As administrative supplements, the work proposed needs to be within the scope of the research or training that is already supported. Awardees are expected to follow-up on the supplement and seek competing support to continue promising leads from the research supported through the supplement.

Awards that currently focus on pain research are not eligible for this program. If an investigator is uncertain whether the parent project does carry a pain focus as defined by NIH, then the investigator may contact the appropriate program officer who can check that status.

All grant awards made by NINDS are eligible with the exception of the following mechanisms: F30, F31, F32, T32, T35, K99, R13, and U13. Eligibility criteria can be found within PA-20-272.

The goal of the supplement should be to add a pain component to the parent project, where a significant pain component does not exist. Examples of parent project research areas for which administrative supplements will be considered include, but are not limited to:

• Stroke
• Spinal cord injury
• Traumatic brain injury
• Multiple sclerosis
• Movement disorders, including Parkinson Disease, Huntington’s disease, dystonia, and tremor
• Dementias, including frontotemporal dementias
• Neuromuscular disorders including amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA)
• Vascular contributions to dementia, including vascular cognitive impairment and vascular dementia
• Headache
• Autism and other neurodevelopmental disorders
• Epilepsy

Application and Submission Information

Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent.

• PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

All instructions in the SF424 (R&R) Application Guide and PA-20-272 must be followed, with the following additions:

• Application Due Date(s) – June 1, 2022, by 5:00 PM local time of applicant organization.
• For funding consideration, applicants must include “NOT-NS-22-053” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.
• Only electronic submissions will be accepted for this funding opportunity. Use one of the methods described in PA-20-272. Paper submissions and applications submitted as attachments will be returned.
• Requests may be for one year of support only.
• Individual requests can be no more than $200,000 in direct costs exclusive of Facilities and Administrative costs on sub-contracts. Though supplement requests are not limited to one per award, we will consider substantial additional funding to an award as beyond the scope of the funded award.
• Applicants may apply for more than one supplement to a given parent grant/award, provided they are scientifically distinct.
• The Research Strategy section of the application is limited to 6 pages.
• As part of the application, investigators must submit an abstract of the proposed research that shows the relevance to pain research. Place the abstract in the Project Summary/Abstract section of the SF424 (R&R) form. The work may include pilot projects or resource development.

Review Process

NINDS will conduct an administrative review of the applications.

Criteria:

1. Is the work proposed within the scope of the active award?
2. Is the work proposed focused on pain?
3. Is the work likely to stimulate additional activity leading to progress in pain research or its treatment?

Inquiries

Please direct all inquiries to:

Michael L. Oshinsky, PhD
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-9964
Email: michael.oshinsky@nih.gov

D.P. Mohapatra, PhD
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-9964
Email: dp.mohapatra@nih.gov

Julia L. Bachman, PhD
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-827-7383
Email: julia.bachman@nih.gov